Mankind Pharma shares gain as Q2 profit jumps 38%
By Rohit SharmaMarkets Analyst, Peepals Business
Representative image: jarmoluk / Pixabay
Mankind Pharma's shares gained over 4% after it reported on October 26, 2026, a 37.7% rise in July-September profit to Rs 716.12 crore on 17% revenue growth.
What Happened
Shares of Mankind Pharma rose more than 4% after the drugmaker reported a sharp jump in quarterly profit, according to market reports. For the July-September 2026 quarter, the company's consolidated net profit after tax rose 37.7% to Rs 716.12 crore from Rs 520.18 crore a year earlier; profit attributable to the parent company's shareholders was Rs 711.48 crore. Revenue from operations rose 17.3% to about Rs 4,338 crore, and the company's operating margin widened. The results were released on Monday, October 26.
Key Facts
- Net profit after tax: Rs 716.12 crore, up 37.7% from Rs 520.18 crore.
- Profit attributable to shareholders of the parent: Rs 711.48 crore (the basis for headlines citing a 39% rise).
- Revenue from operations: about Rs 4,338 crore, up 17.3% from about Rs 3,697 crore.
- EBITDA (operating profit): Rs 1,175 crore, up 27.2%; margin 27.1%, against 25.0% a year earlier.
- Domestic business excluding consumer healthcare: up 15.9%; international business: up 33%.
- Net debt: reduced to about Rs 2,639 crore.
- Board decision: approved merging several wholly owned subsidiaries into the company.
- Share reaction: up more than 4% after the results, according to market reports.
Why It Matters
Mankind Pharma sells prescription medicines and consumer health products, and most of its revenue comes from India. Its results are therefore one gauge of demand for medicines in the domestic market, where the company's business outside consumer healthcare grew 15.9% in the quarter.
The key message in the numbers is profitability. Profit grew more than twice as fast as revenue, because operating costs rose more slowly than sales. EBITDA, short for earnings before interest, taxes, depreciation and amortisation, measures profit from day-to-day operations; a margin of 27.1% means that out of every Rs 100 of sales, about Rs 27 was left as operating profit, up from Rs 25 a year earlier. Reports said the result was also ahead of what analysts had expected, with one citing a consensus estimate of about Rs 615 crore.
The international business, growing at 33%, is still smaller than the domestic one but is adding to growth. Lower net debt, the amount a company owes minus the cash it holds, means less money going to interest payments, which supports future profits and leaves more room for investment. The planned merger of subsidiaries is an internal restructuring meant to simplify the company's structure; it does not change who owns the business.
For the market, the share price rise shows investors reacting to profits ahead of estimates. Share prices move for many reasons, and a single day's gain says little about the future; this story does not offer any view on whether to buy or sell the stock.
| Measure | July-September 2026 | July-September 2025 |
|---|---|---|
| Net profit after tax | Rs 716.12 crore | Rs 520.18 crore |
| Revenue from operations | About Rs 4,338 crore | About Rs 3,697 crore |
| EBITDA margin | 27.1% | 25.0% |
Impact
Short-term: The results lifted sentiment around the stock, with the share price rising more than 4% after the announcement.
Long-term: Higher margins, lower debt and a growing overseas business give the company more room to invest in new products and acquisitions, though future results will depend on price controls, competition and demand.
Who is affected: The company's shareholders and employees, doctors and patients who use its medicines, its distributors and chemists, and rival drugmakers.
Key Takeaway
Mankind Pharma's September-quarter profit rose 37.7% to Rs 716.12 crore on 17% revenue growth and a wider 27.1% margin, and its shares gained more than 4% after the announcement.
Questions and Answers
What were Mankind Pharma's Q2 FY27 results?
For July-September 2026, net profit after tax rose 37.7% to Rs 716.12 crore, revenue from operations rose 17.3% to about Rs 4,338 crore, and the EBITDA margin improved to 27.1%.
Why do some reports say profit rose 39%?
They use profit attributable to the parent company's shareholders, Rs 711.48 crore, rather than total profit after tax, Rs 716.12 crore.
How did Mankind Pharma shares react?
The shares rose more than 4% after the results were announced, according to market reports.
What did the board approve alongside the results?
It approved merging several wholly owned subsidiaries into the company, an internal restructuring to simplify its corporate structure.
Which parts of Mankind Pharma's business grew fastest?
The international business grew 33%, faster than the domestic business excluding consumer healthcare, which grew 15.9%. The domestic market still provides most of the company's revenue.
Disclaimer: Prepared by the Peepals newsroom from publicly available sources with AI assistance. Information is accurate to the best of our knowledge at the time of publication and may change. Images may be representative. Not professional advice. Report an error via our contact page.
By Rohit Sharma, Markets AnalystCovers Markets Watch and more for Peepals Business. All stories by Rohit Sharma
India, Netherlands discuss chips, critical minerals as Goyal pushes EU pact
Kerala approves India's first cooperative-sector airline, plans Kochi flights
Get the day's stories in your inbox
Peepals Weekly: the week decoded, free. One email a week, unsubscribe in one click.
Rohit Sharma is a pen name of the Peepals Global Editorial Team, which researches, fact-checks and publishes every story. The portrait is an illustration.
